Influence of metabolic syndrome components on the level of nitric oxide stable metabolites in patients with essential hypertension


Objective. To investigate levels of the stable nitric oxide metabolites (NOx) in relation to different components of the metabolic syndrome (MS) in essential hypertension (EH).Methods. We examined 124 untreated patients with EH and 25 healthy volunteers with comparable age.Results. NOx levels were significantly higher in hypertensives (43.18±21, mol/l) then in controls (28.3±9.6 mol/l); p <0.05. In patients with hyperglycemia NOx concentration was significantly higher (46.5±23.9 mol/l) than in those without it (38.6±18, mol/l); р <0.05. NOx levels correlated with blood glucose levels (r=0.32, p <0.05). Obese hypertensives had lower NOx concentration than nonobese hypertensives (38.8±17.9 and 48.5±24.7mol/l accordingly; р <0.05). NOx levels correlated with the presence (r=-0.44, p <0.05) and degree of obesity (r=-0.3, p <0.05). NOx levels were significantly lower in patients with MS (31.6±11.3 and 47.05±20.7 mol/l accordingly; р <0.05). NOx levels decreased with the increase of the quantity of MS components ( р <0.05). NOx levels correlated with the amount of MS components (r=-0.38, p <0.05). Hypertensives with high leptin levels had lower NOx concentration (29±12.2 mol/l), compared to hypertensives with normal leptin levels (34.7±10.5 mol/l); p <0.05.Conclusion. Hypertension per se and hyperglycemia increase NOx levels, whereas MS and its essential signs like visceral obesity and high plasma leptin level decrease NOx levels.

Full Text

Restricted Access

About the authors

V I Podzolkov

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

A E Bragina

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

G I Bragina

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

N A Murashko

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2


  1. Викулова О.К,. Ярек-Мартынова И.Р., Трубицина Н.П., Шестакова М.В. Показатели вазомоторной функции эндотелия и эластичности артериальной стенки при терапии ингибиторами ангиотензинпревращающего фермента рамиприлом у больных сахарным диабетом 2 типа. Кардиология. 2008; 10: 47-52.
  2. Дудчак А.П. Оксид азота как маркер риска формирования артериальной гипертензии у детей. Клиническая педиатрия. 2008; 4 (13): 59-62.
  3. Загидуллин Н.Ш., Валеев К.Ф., Гасалов Н., Загидуллин Ш.З. Значение дисфункции эндотелия при сердечно - сосудистых заболеваниях и методы ее медикаментозной коррекции. Кардиология. 2010; 5: 54-60.
  4. Кушнаренко Н.Н., Говорин А.В., Кушнаренко К.Е. Состояние функции эндотелия у больных подагрой с артериальной гипертензией. Системные гипертензии. 2012; 9: 48-52.
  5. Манухина Е.Б., Лямина Н.П., Долотовская П.В. и др. Роль оксида азота и кислородных свободных радикалов в патогенезе артериальной гипертензии. Кардиология. 2002; 5: 55-63.
  6. Манухина Е.Б., Малышев И.Ю., Бувальце В.И. Эндотелиальная дисфункция и артериальная гипертензия: механизмы и пути коррекции. Кардиоваскулярная терапия и профилактика. 2003; 4: 26-30.
  7. Марков Х.М. Оксид азота и атеросклероз. Оксид азота, дисфункция сосудистого эндотелия и патогенез атеросклероза. Кардиология. 2009; 11: 64-74.
  8. Недогода С.В. Ожирение и артериальная гипертензия: теория и практика выбора оптимального гипотензивного препарата. М.: Медиком, 2012: 3-26.
  9. Олейников В.Э., Матросова И.Б. Клиническое исследование артериальной ригидности. Ремоделирование сосудов при артериальной гипертонии и метаболическом синдроме. Возможности медикаментозной коррекции. Кардиология. 2009; 12: 51-7.
  10. Ройтберг Г.Е., Ушакова Т.И., Шархун О.О, Дорош Ж.В. Интегральный подход к диагностике метаболического синдрома в клинической практике. Кардиология. 2012; 10: 45-50.
  11. Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2008.
  12. Шамансурова З.М. Уровень стабильных метаболитов оксида азота в крови при метаболическом синдроме и сахарном диабете. Сахарный диабет. 2011; 3: 71-4.
  13. Шварц В.Я. Воспаление жировой ткани и атеросклероз. Кардиология. 2009; 13: 80-6.
  14. Яновская Г.Р., Белов В.В., Болотов А.А. Функция эндотелия у молодых мужчин с эссенциальной гипертонией. Рос. кардиол. журн. 2004; 3: 21-6.
  15. Lekakis J, Abraham P et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation European Journal of Cardiovascular Prevention & Rehabilitation 2011; 8.
  16. Higashi Y, Nakagawa K et al. Circadian variation of blood pressure and endothelial function in patients with essential hypertension: a comparison of dippers and non - dippers. J Am Coll Cardiol 2002; 40 (11).
  17. Pierdomenico S.D, Cipollone F et al. Endothelial function in sustained and white coat hypertension. Am J Hypertens 2002; 15 (11).
  18. Chowdhary S, Townend J.N. Nitric oxide and hypertension: not just an endothelium derived relaxing factor. J Human Hypertens 2001; 15.
  19. Jeong-Ho Oak, Hua Cai. Attenuation of Angiotensin II Signaling Recouples eNOS and Inhibits Nonendothelial NOX Activity. Diabetic Diabetes 2007; 56 (1).
  20. Dikalova A.E, Góngora M.C et al. Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium - dependent relaxation via eNOS uncoupling. Am J Physiol Heart Circ Physiol 2010; 299 (3).
  21. Moriel P et al. Nitric oxide, cholesterol oxides and endothelium - dependent vasodilation in plasma of patients with essential hypertension NO derivatives and cholesterol oxides in hypertension. Braz J Med Biol Res 2002; 35.
  22. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10 (4): S1-S10.
  23. Simko A.N, Lozovoy M.A, Simko T.N, Venturini D. Immunological and biochemical parameters of patients with metabolic syndrome and the participation of oxidative and nitroactive stress. Braz J Med Biol Res 2011; 44 (7): 707-12.
  24. Bi’e Tan, Xinguo Li, Yulong Yin, Zhenlong Wu. Regulatory roles for L-arginine in reducing white adipose tissue. Front Biosci 2012; 17: 2237-46.
  25. Huang P.L. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009; 20 (6): 295-302.
  26. Ghiadoni L, Magagna A, Versari D et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-6.
  27. Giuntoli F, Huang S.S et al. Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J 2009; 73: 2282-7.
  28. Ludwig D.S. Chaildhood Obesity - The Shape of Things to Come. N Engl J Med 2007; 357: 2325.
  29. Williams I.L, Wheatcroft S.B, Shah A.M, Kearney M.T. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obesity 2002; 26: 754-64.
  30. Meadows J.L, Douglas E. Vaughan/Endothelial biology in the post - menopausal obese woman. Maturitas 69 2011: 120-5.
  31. Hong H-J, Loh S-H, Yen M-H. Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase. Br J Pharmacol 2000; 131: 631-7.
  32. Jianping Ye. Adipose Tissue Vascularization: Its Role in Chronic Inflammation/ Curr Diab Rep 2011; 11 (3): 203-10. doi: 10.1007/s11892-011-0183-1.



Abstract - 11

PDF (Russian) - 5



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies